SCA
GILD icon

Sippican Capital Advisors’s Gilead Sciences GILD Stock Holding History

Sippican Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,942
Closed -$289K – 117
2024
Q1 		$289K Sell
3,942
-17,346
-81% -$1.33M 0.22% 92
2023
Q4 		$1.72M Sell
21,288
-180
-0.8% -$14K 1.35% 22
2023
Q3 		$1.61M Hold
21,468
– – 1.45% 27
2023
Q2 		$1.65M Sell
21,468
-784
-4% -$62.5K 1.53% 22
2023
Q1 		$1.85M Sell
22,252
-4,167
-16% -$345K 1.77% 14
2022
Q4 		$2.27M Sell
26,419
-2,180
-8% -$173K 2.17% 8
2022
Q3 		$1.76M Buy
28,599
+727
+3% +$45.8K 1.84% 11
2022
Q2 		$1.72M Buy
27,872
+1,667
+6% +$103K 1.71% 15
2022
Q1 		$1.56M Buy
26,205
+6,083
+30% +$389K 1.29% 32
2021
Q4 		$1.46M Buy
20,122
+339
+2% +$23.3K 1.24% 35
2021
Q3 		$1.38M Sell
19,783
-325
-2% -$22.8K 1.2% 33
2021
Q2 		$1.39M Sell
20,108
-830
-4% -$55.4K 1.2% 34
2021
Q1 		$1.35M Buy
20,938
+3,357
+19% +$216K 1.25% 33
2020
Q4 		$1.02M Buy
17,581
+1,408
+9% +$85K 1.11% 36
2020
Q3 		$1.02M Buy
16,173
+688
+4% +$47.7K 1.27% 31
2020
Q2 		$1.19M Sell
15,485
-810
-5% -$62.1K 1.61% 24
2020
Q1 		$1.22M Sell
16,295
-3,699
-19% -$256K 1.98% 12
2019
Q4 		$1.3M Sell
19,994
-2,921
-13% -$190K 1.45% 23
2019
Q3 		$1.45M Buy
22,915
+480
+2% +$31.4K 1.76% 17
2019
Q2 		$1.52M Sell
22,435
-1,921
-8% -$126K 1.79% 17
2019
Q1 		$1.58M Sell
24,356
-96
-0.4% -$6.38K 1.88% 15
2018
Q4 		$1.53M Buy
24,452
+40
+0.2% +$2.8K 2.07% 12
2018
Q3 		$1.75M Buy
24,412
+45
+0.2% +$3.4K 2.03% 11
2018
Q2 		$1.73M Buy
24,367
+2,952
+14% +$208K 1.73% 20
2018
Q1 		$1.61M Buy
21,415
+712
+3% +$56.6K 1.67% 18
2017
Q4 		$1.48M Buy
20,703
+2,204
+12% +$167K 1.45% 27
2017
Q3 		$1.5M Buy
18,499
+1,834
+11% +$140K 1.54% 23
2017
Q2 		$1.18M Buy
16,665
+5,514
+49% +$367K 1.28% 30
2017
Q1 		$757K Buy
11,151
+3,359
+43% +$236K 0.8% 45
2016
Q4 		$558K Buy
+7,792
New +$579K 0.58% 59

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sippican Capital Advisors's GILD Position: Q2 2024 in Review

Sippican Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 3,942 shares — an estimated $289K sold.

Sippican Capital Advisors first reported a position in GILD in Q4 2016 and held it in 30 quarters. The position peaked at $2.27M in Q4 2022. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.

  • Sippican Capital Advisors reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
  • Sippican Capital Advisors sold 3,942 Gilead Sciences shares in Q2 2024, an estimated $289K.
  • Sippican Capital Advisors first reported a position in Gilead Sciences in Q4 2016 and held it in 30 quarters.
  • Sippican Capital Advisors's Gilead Sciences position peaked at $2.27M in Q4 2022.
  • 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.

Based on Sippican Capital Advisors's 13F filing for Q2 2024, filed 6 Aug 2024.